Sol-Gel Q2 Loss Narrows, Phase 3 SGT-610 Readout Set for Late November
SLGL has more than doubled off its 52-week low of $15.538.
Summary
Sol-Gel reported Q2 2026 results and confirmed its Phase 3 SGT-610 trial remains on track for top-line data in late November 2026, with cash runway into Q1 2028.
Key Events · Earnings and Guidance · SLGL
-
Phase 3 SGT-610 Readout Set
Top-line results for the pivotal Gorlin syndrome trial are scheduled for late November 2026, with last patient last visit expected in September 2026. Dropout rate is 9% (10 of 113 patients), below original assumptions.
-
Q2 Financial Results
Revenue was $0.6 million, down from $17.3 million in Q2 2025 due to a one-time IP sale. Net loss was $3.7 million, or $1.13 per share, compared to net income of $11.6 million a year ago.
-
Cash Runway Extended
Cash, cash equivalents, and marketable securities totaled $49.3 million as of June 30, 2026, expected to fund operations into the first quarter of 2028.
-
Pipeline Expansion
Initiated proof-of-concept study in high-frequency BCC (enrollment early October 2026) and neo-adjuvant study in BCC surgery (enrollment October 2026). Filed provisional patent for intra-cystic injectable for odontogenic keratocysts.
Analysis · SLGL · Life Sciences
Sol-Gel reported a Q2 net loss of $3.7 million, an improvement from the $7.4 million loss in the first half, with cash runway into Q1 2028. The pivotal Phase 3 trial of SGT-610 for Gorlin syndrome is on track with a 9% dropout rate, and top-line results are scheduled for late November 2026. The company also expanded its pipeline with new studies in high-frequency BCC and neo-adjuvant BCC surgery, plus a provisional patent for an injectable OKC treatment. These developments position the company for a potential first-in-class approval in a rare disease with high unmet need.
At the time of this filing, SLGL was trading at $78.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $256.9M. The 52-week trading range was $15.54 to $97.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.